{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:07:14Z","timestamp":1760573234853,"version":"build-2065373602"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-04017-4","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:46:14Z","timestamp":1760456774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High expression of polo-like kinase 4 predicts worse progression-free survival in diffuse large B cell lymphoma patients treated with R-CHOP"],"prefix":"10.1186","volume":"23","author":[{"given":"Dehong","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qijie","family":"Ran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"9","key":"4017_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842\u201358.","journal-title":"N Engl J Med"},{"issue":"5","key":"4017_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/j.seminhematol.2023.11.004","volume":"60","author":"SS Wang","year":"2023","unstructured":"Wang SS. Epidemiology and etiology of diffuse large B-cell lymphoma. Semin Hematol. 2023;60(5):255\u201366.","journal-title":"Semin Hematol"},{"issue":"1","key":"4017_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","volume":"63","author":"G Kanas","year":"2022","unstructured":"Kanas G, Ge W, Quek RGW, Keeven K, Nersesyan K, Jon EA. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the united States and Western europe: population-level projections for 2020\u20132025. Leuk Lymphoma. 2022;63(1):54\u201363.","journal-title":"Leuk Lymphoma"},{"issue":"10216","key":"4017_CR4","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","volume":"394","author":"V Poeschel","year":"2019","unstructured":"Poeschel V, Held G, Ziepert M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394(10216):2271\u201381.","journal-title":"Lancet"},{"issue":"1","key":"4017_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03393-9","volume":"20","author":"J He","year":"2022","unstructured":"He J, Chen Z, Xue Q, et al. Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature. J Transl Med. 2022;20(1):186.","journal-title":"J Transl Med"},{"issue":"4","key":"4017_CR6","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.7150\/ijbs.67892","volume":"18","author":"XJ Liang","year":"2022","unstructured":"Liang XJ, Song XY, Wu JL, et al. Advances in multi-omics study of prognostic biomarkers of diffuse large B-cell lymphoma. Int J Biol Sci. 2022;18(4):1313\u201327.","journal-title":"Int J Biol Sci"},{"issue":"9","key":"4017_CR7","doi-asserted-by":"publisher","first-page":"300060522111007","DOI":"10.1177\/03000605221110075","volume":"50","author":"T Yin","year":"2022","unstructured":"Yin T, Qi L, Zhou Y, et al. CD5\u2009+\u2009diffuse large B-cell lymphoma has heterogeneous clinical features and poor prognosis: a single-center retrospective study in China. J Int Med Res. 2022;50(9):3000605221110075.","journal-title":"J Int Med Res"},{"issue":"7","key":"4017_CR8","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1007\/s10238-023-01127-9","volume":"23","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wang J, Shen X, et al. A novel angiogenesis-related scoring model predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma. Clin Exp Med. 2023;23(7):3781\u201397.","journal-title":"Clin Exp Med"},{"issue":"3","key":"4017_CR9","volume":"10","author":"JH Lee","year":"2024","unstructured":"Lee JH, Song GY, Lee J, et al. Prediction of immunochemotherapy response for diffuse large B-cell lymphoma using artificial intelligence digital pathology. The Journal of Pathology: Clinical Research. 2024;10(3):e12370.","journal-title":"The Journal of Pathology: Clinical Research"},{"key":"4017_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104884","volume":"215","author":"AH Aghayan","year":"2025","unstructured":"Aghayan AH, Bayani A, Abbaspour M, Gharehchahi F, Soleimani Samarkhazan H. Extracellular vesicle-based biomarkers in diffuse large B-cell lymphoma: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2025;215:104884.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4017_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113314","volume":"217","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Xing X, Guan P, et al. Recent progress in agents targeting polo-like kinases: promising therapeutic strategies. Eur J Med Chem. 2021;217:113314.","journal-title":"Eur J Med Chem"},{"key":"4017_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.587554","volume":"11","author":"X Zhang","year":"2021","unstructured":"Zhang X, Wei C, Liang H, Han L. Polo-like kinase 4\u2019s critical role in cancer development and strategies for Plk4-targeted therapy. Front Oncol. 2021;11:587554.","journal-title":"Front Oncol"},{"key":"4017_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cells11050786","author":"I Hoffmann","year":"2022","unstructured":"Hoffmann I. Role of Polo-like kinases Plk1 and Plk4 in the initiation of centriole duplication-impact on cancer. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11050786.","journal-title":"Cells"},{"issue":"4","key":"4017_CR14","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/1535-7163.MCT-20-0741","volume":"20","author":"DR Garvey","year":"2021","unstructured":"Garvey DR, Chhabra G, Ndiaye MA, Ahmad N. Role of Polo-like kinase 4 (PLK4) in epithelial cancers and recent progress in its small molecule targeting for cancer management. Mol Cancer Ther. 2021;20(4):632\u201340.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"4017_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2023.2223383","volume":"24","author":"W Zhu","year":"2023","unstructured":"Zhu W, Xie B. PLK4 inhibitor exhibits antitumor effect and synergizes Sorafenib via arresting cell cycle and inactivating Wnt\/beta-catenin pathway in anaplastic thyroid cancer. Cancer Biol Ther. 2023;24(1):2223383.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"4017_CR16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/hep.32461","volume":"77","author":"CY Chan","year":"2023","unstructured":"Chan CY, Yuen VW, Chiu DK, et al. Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity. Hepatology. 2023;77(3):729\u201344.","journal-title":"Hepatology"},{"issue":"2","key":"4017_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3892\/ol.2022.13389","volume":"24","author":"Z Duan","year":"2022","unstructured":"Duan Z, Cai L, Cao J, Wu W. Polo-like kinase 4 is associated with advanced TNM stages and reduced survival and its inhibition improves chemosensitivity in colorectal cancer. Oncol Lett. 2022;24(2):269.","journal-title":"Oncol Lett"},{"key":"4017_CR18","doi-asserted-by":"publisher","first-page":"6302234","DOI":"10.1155\/2022\/6302234","volume":"2022","author":"C Hu","year":"2022","unstructured":"Hu C, Liu Q, Hu C, Wang Y, Wang P, Zhou X. PLK4 is a potential biomarker for abnormal tumor proliferation, immune infiltration, and prognosis in CcRCC. Comput Math Methods Med. 2022;2022:6302234.","journal-title":"Comput Math Methods Med"},{"issue":"4","key":"4017_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23152","volume":"34","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, Fan G, Dong Y. Polo-like kinase 4 correlates with greater tumor size, lymph node metastasis and confers poor survival in non-small cell lung cancer. J Clin Lab Anal. 2020;34(4):e23152.","journal-title":"J Clin Lab Anal"},{"issue":"1","key":"4017_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41388-018-0443-5","volume":"38","author":"O Goroshchuk","year":"2019","unstructured":"Goroshchuk O, Kolosenko I, Vidarsdottir L, Azimi A, Palm-Apergi C. Polo-like kinases and acute leukemia. Oncogene. 2019;38(1):1\u201316.","journal-title":"Oncogene"},{"issue":"23","key":"4017_CR21","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1182\/blood.2023021950","volume":"142","author":"C Palm-Apergi","year":"2023","unstructured":"Palm-Apergi C. PLK4, a potential target against AML. Blood. 2023;142(23):1941\u20132.","journal-title":"Blood"},{"issue":"23","key":"4017_CR22","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1182\/blood.2023019782","volume":"142","author":"CH Man","year":"2023","unstructured":"Man CH, Lam W, Dang CC, et al. Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML. Blood. 2023;142(23):2002\u201315.","journal-title":"Blood"},{"issue":"2","key":"4017_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s11845-022-03007-9","volume":"192","author":"B Xu","year":"2023","unstructured":"Xu B, Li J, Xu D, Ran Q. PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K\/AKT signaling. Ir J Med Sci. 2023;192(2):561\u201367.","journal-title":"Ir J Med Sci"},{"issue":"12","key":"4017_CR24","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1080\/10428194.2016.1177179","volume":"57","author":"SD Hudnall","year":"2016","unstructured":"Hudnall SD, Meng H, Lozovatsky L, Li P, Strout M, Kleinstein SH. Recurrent genetic defects in classical hodgkin lymphoma cell lines. Leuk Lymphoma. 2016;57(12):2890\u2013900.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"4017_CR25","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41419-021-03919-x","volume":"12","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Yang J, Liu J, et al. Inhibition of polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma. Cell Death Dis. 2021;12(7):640.","journal-title":"Cell Death Dis"},{"issue":"1","key":"4017_CR26","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1080\/07853890.2022.2046287","volume":"54","author":"KO Gradel","year":"2022","unstructured":"Gradel KO, Larsen TS, Frederiksen H, et al. Impact of C-reactive protein and albumin levels on short, medium, and long term mortality in patients with diffuse large B-cell lymphoma. Ann Med. 2022;54(1):713\u201322.","journal-title":"Ann Med"},{"issue":"Suppl 3","key":"4017_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/10428190310001623775","volume":"44","author":"A Rosenwald","year":"2003","unstructured":"Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma. 2003;44(Suppl 3):41\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"4017_CR28","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/leu.2013.224","volume":"28","author":"KK Wong","year":"2014","unstructured":"Wong KK, Gascoyne DM, Brown PJ, et al. Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients. Leukemia. 2014;28(2):362\u201372.","journal-title":"Leukemia"},{"issue":"6","key":"4017_CR29","first-page":"5327","volume":"18","author":"Y He","year":"2018","unstructured":"He Y, Wang H, Yan M, et al. High LIN28A and PLK4 co\u2013expression is associated with poor prognosis in epithelial ovarian cancer. Mol Med Rep. 2018;18(6):5327\u201336.","journal-title":"Mol Med Rep"},{"key":"4017_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering5040096","author":"AW Bailey","year":"2018","unstructured":"Bailey AW, Suri A, Chou PM, et al. Polo-like kinase 4 (PLK4) is overexpressed in central nervous system neuroblastoma (CNS-NB). Bioengineering. 2018. https:\/\/doi.org\/10.3390\/bioengineering5040096.","journal-title":"Bioengineering"},{"key":"4017_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154376","volume":"243","author":"S Chen","year":"2023","unstructured":"Chen S, Zhong L, Chu X, et al. Downregulation of Polo-like kinase 4 induces cell apoptosis and G2\/M arrest in acute myeloid leukemia. Pathol Res Pract. 2023;243:154376.","journal-title":"Pathol Res Pract"},{"key":"4017_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1055371","volume":"12","author":"X Zhang","year":"2022","unstructured":"Zhang X, Li Z, Wei C, et al. PLK4 initiates crosstalk between cell cycle, cell proliferation and macrophages infiltration in gliomas. Front Oncol. 2022;12:1055371.","journal-title":"Front Oncol"},{"issue":"9","key":"4017_CR33","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.7150\/jca.74211","volume":"13","author":"F Fu","year":"2022","unstructured":"Fu F, Chen L, Yang X, et al. PLK4 is a key molecule in the formation of PGCCs and promotes invasion and migration of progeny cells derived from PGCCs. J Cancer. 2022;13(9):2954\u201369.","journal-title":"J Cancer"},{"issue":"2","key":"4017_CR34","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/0008-5472.CAN-16-2060","volume":"77","author":"K Kazazian","year":"2017","unstructured":"Kazazian K, Go C, Wu H, et al. Plk4 promotes cancer invasion and metastasis through Arp2\/3 complex regulation of the actin cytoskeleton. Cancer Res. 2017;77(2):434\u201347.","journal-title":"Cancer Res"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04017-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04017-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04017-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T02:16:13Z","timestamp":1760494573000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-04017-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4017"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04017-4","relation":{},"ISSN":["1477-7819"],"issn-type":[{"type":"electronic","value":"1477-7819"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received approval from the Ethics Committee. All the participants or their families provided informed consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"375"}}